Research hotspots of polycystic ovary syndrome and hyperandrogenism from 2008 to 2022: bibliometric analysis

References

• Franik S, Le Q-K, Kremer JA, et al. Aromatase inhibitors (letrozole) for ovulation induction in infertile women with polycystic ovary syndrome. Cochrane Database Syst Rev. 2022;9(9):1. doi: 10.1002/14651858.CD010287.pub4.
   Google Scholar
• Bozdag G, Mumusoglu S, Zengin D, et al. The prevalence and phenotypic features of polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod. 2016;31(12):2841–10. doi: 10.1093/humrep/dew218.
   PubMed Web of Science ®Google Scholar
• Deswal R, Narwal V, Dang A, et al. The prevalence of polycystic ovary syndrome: a brief systematic review. J Hum Reprod Sci. 2020;13(4):261–271. doi: 10.4103/jhrs.JHRS_95_18.
   PubMedGoogle Scholar
• Rosenfield RL, Ehrmann DA. The pathogenesis of polycystic ovary syndrome (PCOS): the hypothesis of PCOS as functional ovarian hyperandrogenism revisited. Endocr Rev. 2016;37(5):467–520. doi: 10.1210/er.2015-1104.
   PubMed Web of Science ®Google Scholar
• Azziz R, Sanchez LA, Knochenhauer ES, et al. Androgen excess in women: experience with over 1000 consecutive patients. J Clin Endocrinol Metab. 2004;89(2):453–462. doi: 10.1210/jc.2003-031122.
   PubMed Web of Science ®Google Scholar
• Zhang CY, Li H, Zhang S, et al. Abnormal uterine bleeding patterns determined through menstrual tracking among participants in the apple women?s health study. Am J Obstet Gynecol. 2023;228(2):213.e1–213.e22. doi: 10.1016/j.ajog.2022.10.029.
   PubMed Web of Science ®Google Scholar
• El Mahdi E, Fekry N, Ahmed M, et al. Testosterone, sex hormone-binding globulin and dehydroepiandrosterone levels and cervical length of Egyptian women with a history of recurrent miscarriages, polycystic ovary syndrome and without the conditions at three stages of pregnancy. J Obstetr Gynaecol. 2023;43(1):2163625. doi: 10.1080/01443615.2022.2163625.
   Web of Science ®Google Scholar
• Oberg E, Blomberg L, Åkerstedt T, et al. Different sleep pattern in over-weight/obese women with polycystic ovary syndrome. Front Endocrinol (Lausanne). 2023;14:1068045. doi: 10.3389/fendo.2023.1068045.
   PubMed Web of Science ®Google Scholar
• Patten RK, McIlvenna LC, Moreno-Asso A, et al. Efficacy of high-intensity interval training for improving mental health and health-related quality of life in women with polycystic ovary syndrome. Sci Rep. 2023;13(1):3025. doi: 10.1038/s41598-023-29503-1.
   PubMed Web of Science ®Google Scholar
• Barry JA, Azizia MM, Hardiman PJ. Risk of endometrial, ovarian and breast cancer in women with polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update. 2014;20(5):748–758. doi: 10.1093/humupd/dmu012.
   PubMed Web of Science ®Google Scholar
• Azziz R, Carmina E, Chen Z, et al. Polycystic ovary syndrome. Nat Rev Dis Primers. 2016;2(1):16057. doi: 10.1038/nrdp.2016.57.
   PubMed Web of Science ®Google Scholar
• Chen T, Yu Y, Jia F, et al. The relationship between polycystic ovary syndrome and insulin resistance from 1983 to 2022: a bibliometric analysis. Front Public Health. 2022;10:960965. doi: 10.3389/fpubh.2022.960965.
   PubMed Web of Science ®Google Scholar
• van Eck NJ, Waltman L. Citation-based clustering of publications using CitNetExplorer and VOSviewer. Scientometrics. 2017;111(2):1053–1070. doi: 10.1007/s11192-017-2300-7.
   PubMed Web of Science ®Google Scholar
• Chen C, Hu Z, Liu S, et al. Emerging trends in regenerative medicine: a scientometric analysis in CiteSpace. Expert Opin Biol Ther. 2012;12(5):593–608. doi: 10.1517/14712598.2012.674507.
   PubMed Web of Science ®Google Scholar
• Chen CM. CiteSpace II: detecting and visualizing emerging trends and transient patterns in scientific literature. J Am Soc Inf Sci. 2006;57(3):359–377. doi: 10.1002/asi.20317.
   Web of Science ®Google Scholar
• Yang Z, Fan Z, Wang D, et al. Bibliometric and visualization analysis of stem cell therapy for meniscal regeneration from 2012 to 2022. Front Bioeng Biotechnol. 2023;11:1107209. doi: 10.3389/fbioe.2023.1107209.
   PubMed Web of Science ®Google Scholar
• Zhu G, Fu Z, Su S, et al. Global trends and hotspots in trigeminal neuralgia research from 2001 to 2021: a bibliometric analysis. Front Neurol. 2022;13:894006. doi: 10.3389/fneur.2022.894006.
   PubMed Web of Science ®Google Scholar
• Hu S, Alimire A, Lai Y, et al. Trends and frontiers of research on cancer gene therapy from 2016 to 2020: a bibliometric analysis. Front Med (Lausanne). 2021;8:740710. doi: 10.3389/fmed.2021.740710.
   PubMed Web of Science ®Google Scholar
• Shan M, Dong Y, Chen J, et al. Global tendency and frontiers of research on myopia from 1900 to 2020: a bibliometrics analysis. Front Public Health. 2022;10:846601. doi: 10.3389/fpubh.2022.846601.
   PubMed Web of Science ®Google Scholar
• Chen Y, Zhang Q, Ma J, et al. Mapping research trends of insulin resistance in polycystic ovary syndrome from 2017 to 2021: a bibliometric analysis. Front Endocrinol (Lausanne). 2022;13:963213. doi: 10.3389/fendo.2022.963213.
   PubMed Web of Science ®Google Scholar
• Sir-Petermann T, Codner E, Pérez V, et al. Metabolic and reproductive features before and during puberty in daughters of women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2009;94(6):1923–1930. doi: 10.1210/jc.2008-2836.
   PubMed Web of Science ®Google Scholar
• Jones H, Sprung VS, Pugh CJA, et al. Polycystic ovary syndrome with hyperandrogenism is characterized by an increased risk of hepatic steatosis compared to nonhyperandrogenic PCOS phenotypes and healthy controls, independent of obesity and insulin resistance. J Clin Endocrinol Metab. 2012;97(10):3709–3716. doi: 10.1210/jc.2012-1382.
   PubMed Web of Science ®Google Scholar
• Lunddorf LLH, Arendt LH, Ernst A, et al. Maternal polycystic ovarian syndrome and pubertal development in daughters and sons: a population-based cohort study. Hum Reprod. 2022;37(11):2623–2634. doi: 10.1093/humrep/deac197.
   PubMed Web of Science ®Google Scholar
• Huang-Doran I, Kinzer AB, Jimenez-Linan M, et al. Ovarian hyperandrogenism and response to gonadotropin-releasing hormone analogues in primary severe insulin resistance. J Clin Endocrinol Metab. 2021;106(8):2367–2383. doi: 10.1210/clinem/dgab275.
   PubMed Web of Science ®Google Scholar
• Rashid A, Masood A, Wani IA, et al. Left ventricular myocardial mass index and its correlates as an early marker of cardiovascular risk among nonobese normotensive Indian women with polycystic ovary syndrome: lessons from a cross-sectional study. Fertil Steril. 2020;113(6):1299–1307.e2. doi: 10.1016/j.fertnstert.2020.02.001.
   PubMed Web of Science ®Google Scholar
• Zore T, Lizneva D, Brakta S, et al. Minimal difference in phenotype between adolescents and young adults with polycystic ovary syndrome. Fertil Steril. 2019;111(2):389–396. doi: 10.1016/j.fertnstert.2018.10.020.
   PubMed Web of Science ®Google Scholar
• Yasmin A, Roychoudhury S, Paul Choudhury A, et al. Polycystic ovary syndrome: an updated overview foregrounding impacts of ethnicities and geographic variations. Life-Basel. 2022;12(12):1974. doi: 10.3390/life12121974.
   PubMed Web of Science ®Google Scholar
• March WA, Moore VM, Willson KJ, et al. The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. Hum Reprod. 2010;25(2):544–551. doi: 10.1093/humrep/dep399.
   PubMed Web of Science ®Google Scholar
• Li R, Zhang Q, Yang D, et al. Prevalence of polycystic ovary syndrome in women in China: a large community-based study. Hum Reprod. 2013;28(9):2562–2569. doi: 10.1093/humrep/det262.
   PubMed Web of Science ®Google Scholar
• Ranathunga I, Athukorala TG, Sumanatilleke MR, et al. Evaluation of socio-demographic and clinical characteristics of PCOS patients attending a tertiary care institute in Colombo. BMC Endocr Disord. 2022;22(1):289. doi: 10.1186/s12902-022-01206-0.
   PubMed Web of Science ®Google Scholar
• Giménez-Peralta I, Lilue M, Mendoza N, et al. Application of a new ultrasound criterion for the diagnosis of polycystic ovary syndrome. Front Endocrinol. 2022;13:915245. doi: 10.3389/fendo.2022.915245.
   PubMed Web of Science ®Google Scholar
• Hayes MG, Urbanek M, Ehrmann DA, et al. Genome-wide association of polycystic ovary syndrome implicates alterations in gonadotropin secretion in European ancestry populations. Nat Commun. 2015;6(1):7502. doi: 10.1038/ncomms8502.
   PubMedGoogle Scholar
• McAllister JM, Legro RS, Modi BP, et al. Functional genomics of PCOS: from GWAS to molecular mechanisms. Trends Endocrinol Metab. 2015;26(3):118–124. doi: 10.1016/j.tem.2014.12.004.
   PubMed Web of Science ®Google Scholar
• Stepto NK, Cassar S, Joham AE, et al. Women with polycystic ovary syndrome have intrinsic insulin resistance on euglycaemic-hyperinsulaemic clamp. Hum Reprod. 2013;28(3):777–784. doi: 10.1093/humrep/des463.
   PubMed Web of Science ®Google Scholar
• Palomba S, de Wilde MA, Falbo A, et al. Pregnancy complications in women with polycystic ovary syndrome. Hum Reprod Update. 2015;21(5):575–592. doi: 10.1093/humupd/dmv029.
   PubMed Web of Science ®Google Scholar
• Patel S. Polycystic ovary syndrome (PCOS), an inflammatory, systemic, lifestyle endocrinopathy. J Steroid Biochem Mol Biol. 2018;182:27–36. doi: 10.1016/j.jsbmb.2018.04.008.
   PubMed Web of Science ®Google Scholar
• Azziz R. Polycystic ovary syndrome. Obstet Gynecol. 2018;132(2):321–336. doi: 10.1097/AOG.0000000000002698.
   PubMed Web of Science ®Google Scholar
• Zeng X, Xie Y-J, Liu Y-T, et al. Polycystic ovarian syndrome: correlation between hyperandrogenism, insulin resistance and obesity. Clin Chim Acta. 2020;502:214–221. doi: 10.1016/j.cca.2019.11.003.
   PubMed Web of Science ®Google Scholar
• Eini F, Kutenaei MA, Foroutan T, et al. High levels of follicular fluid testosterone could impair oocyte developmental competency via affecting aryl hydrocarbon receptor pathway in PCOS patients. BMC Mol Cell Biol. 2022;23(1):47. doi: 10.1186/s12860-022-00449-y.
   PubMed Web of Science ®Google Scholar
• Cox MJ, Edwards MC, Rodriguez Paris V, et al. Androgen action in adipose tissue and the brain are key mediators in the development of PCOS traits in a mouse model. Endocrinology. 2020;161(7):bqaa061. doi: 10.1210/endocr/bqaa061.
   Web of Science ®Google Scholar
• Xiong T, Rodriguez Paris V, Edwards MC, et al. Androgen signaling in adipose tissue, but less likely skeletal muscle, mediates development of metabolic traits in a PCOS mouse model. Am J Physiol Endocrinol Metab. 2022;323(2):E145–E158. doi: 10.1152/ajpendo.00418.2021.
   PubMed Web of Science ®Google Scholar
• Ferrer MJ, Abruzzese GA, Heber MF, et al. Intrauterine androgen exposure impairs gonadal adipose tissue functions of adult female rats. Theriogenology. 2023;198:131–140. doi: 10.1016/j.theriogenology.2022.12.035.
   PubMed Web of Science ®Google Scholar
• Catteau-Jonard S, Jamin SP, Leclerc A, et al. Anti-mullerian hormone, its receptor, FSH receptor, and androgen receptor genes are overexpressed by granulosa cells from stimulated follicles in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2008;93(11):4456–4461. doi: 10.1210/jc.2008-1231.
   PubMed Web of Science ®Google Scholar
• Franks S, Stark J, Hardy K. Follicle dynamics and anovulation in polycystic ovary syndrome. Hum Reprod Update. 2008;14(4):367–378. doi: 10.1093/humupd/dmn015.
   PubMed Web of Science ®Google Scholar
• Dewailly D, Pigny P, Soudan B, et al. Reconciling the definitions of polycystic ovary syndrome: the ovarian follicle number and serum anti-mullerian hormone concentrations aggregate with the markers of hyperandrogenism. J Clin Endocrinol Metab. 2010;95(9):4399–4405. doi: 10.1210/jc.2010-0334.
   PubMed Web of Science ®Google Scholar
• Shorakae S, Teede H, de Courten B, et al. The emerging role of chronic low-grade inflammation in the pathophysiology of polycystic ovary syndrome. Semin Reprod Med. 2015;33(4):257–269. doi: 10.1055/s-0035-1556568.
   PubMed Web of Science ®Google Scholar
• Hu M, Zhang Y, Lu Y, et al. Regulatory mechanisms of HMGB1 and its receptors in polycystic ovary syndrome-driven gravid uterine inflammation. FEBS J. 2023;290(7):1874–1906. doi: 10.1111/febs.16678.
   PubMed Web of Science ®Google Scholar
• Hu M, Zhang Y, Guo X, et al. Hyperandrogenism and insulin resistance induce gravid uterine defects in association with mitochondrial dysfunction and aberrant reactive oxygen species production. Am J Physiol Endocrinol Metab. 2019;316(5):E794–E809. doi: 10.1152/ajpendo.00359.2018.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zhao W, Xu H, et al. Hyperandrogenism and insulin resistance-induced fetal loss: evidence for placental mitochondrial abnormalities and elevated reactive oxygen species production in pregnant rats that mimic the clinical features of polycystic ovary syndrome. J Physiol. 2019;597(15):3927–3950. doi: 10.1113/JP277879.
   PubMed Web of Science ®Google Scholar
• Sun Y, Li S, Liu H, et al. Oxidative stress promotes hyperandrogenism by reducing sex hormone-binding globulin in polycystic ovary syndrome. Fertil Steril. 2021;116(6):1641–1650. doi: 10.1016/j.fertnstert.2021.07.1203.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Hu M, Meng F, et al. Metformin ameliorates uterine defects in a rat model of polycystic ovary syndrome. Ebiomedicine. 2017;18:157–170. doi: 10.1016/j.ebiom.2017.03.023.
   PubMed Web of Science ®Google Scholar
• Hu M, Zhang Y, Ma S, et al. Suppression of uterine and placental ferroptosis by N-acetylcysteine in a rat model of polycystic ovary syndrome. Mol Hum Reprod. 2021;27(12):gaab067. doi: 10.1093/molehr/gaab067.
   Web of Science ®Google Scholar
• Zhao JF, Li BX, Zhang Q. Vitamin D improves levels of hormonal, oxidative stress and inflammatory parameters in polycystic ovary syndrome: a meta-analysis study. Ann Palliat Med. 2021;10(1):169–183. doi: 10.21037/apm-20-2201.
   PubMed Web of Science ®Google Scholar
• Areloegbe SE, Peter MU, Oyeleke MB, et al. Low-dose spironolactone ameliorates adipose tissue inflammation and apoptosis in letrozole-induced PCOS rat model. BMC Endocr Disord. 2022;22(1):224. doi: 10.1186/s12902-022-01143-y.
   PubMed Web of Science ®Google Scholar
• Li W, Hu H, Zou G, et al. Therapeutic effects of puerarin on polycystic ovary syndrome a randomized trial in chinese women. Medicine (Baltimore). 2021;100(21):e26049. doi: 10.1097/MD.0000000000026049.
   PubMed Web of Science ®Google Scholar
• Kwon CY, Cho IH, Park KS. Therapeutic effects and mechanisms of herbal medicines for treating polycystic ovary syndrome: a review. Front Pharmacol. 2020;11:1192. doi: 10.3389/fphar.2020.01192.
   PubMed Web of Science ®Google Scholar
• Balen AH, Morley LC, Misso M, et al. The management of anovulatory infertility in women with polycystic ovary syndrome: an analysis of the evidence to support the development of global WHO guidance. Hum Reprod Update. 2016;22(6):687–708. doi: 10.1093/humupd/dmw025.
   PubMed Web of Science ®Google Scholar
• Crisosto N, Echiburú B, Maliqueo M, et al. Improvement of hyperandrogenism and hyperinsulinemia during pregnancy in women with polycystic ovary syndrome: possible effect in the ovarian follicular mass of their daughters. Fertil Steril. 2012;97(1):218–224. doi: 10.1016/j.fertnstert.2011.10.002.
   PubMed Web of Science ®Google Scholar
• Sir-Petermann T, Ladrón de Guevara A, Codner E, et al. Relationship between anti-mullerian hormone (AMH) and insulin levels during different tanner stages in daughters of women with polycystic ovary syndrome. Reprod Sci. 2012;19(4):383–390. doi: 10.1177/1933719111424444.
   PubMed Web of Science ®Google Scholar
• De Leo V, Musacchio MC, Cappelli V, et al. Genetic, hormonal and metabolic aspects of PCOS: an update. Reprod Biol Endocrinol. 2016;14(1):38. doi: 10.1186/s12958-016-0173-x.
   Google Scholar
• Månsson M, Holte J, Landin-Wilhelmsen K, et al. Women with polycystic ovary syndrome are often depressed or anxious - A case control study. Psychoneuroendocrinology. 2008;33(8):1132–1138. doi: 10.1016/j.psyneuen.2008.06.003.
   PubMed Web of Science ®Google Scholar
• Shawky NM. Cardiovascular disease risk in offspring of polycystic ovary syndrome. Front Endocrinol (Lausanne). 2022;13:977819. doi: 10.3389/fendo.2022.977819.
   PubMed Web of Science ®Google Scholar
• Baptiste CG, Battista M-C, Trottier A, et al. Insulin and hyperandrogenism in women with polycystic ovary syndrome. J Steroid Biochem Mol Biol. 2010;122(1–3):42–52. doi: 10.1016/j.jsbmb.2009.12.010.
   PubMed Web of Science ®Google Scholar
• Hancerliogullari N, Tokmak A, Guney G, et al. Serum calprotectin levels as markers of inflammation, insulin resistance and hyperandrogenism in women with polycystic ovary syndrome. Medicine (Baltimore). 2022;101(51):e32326. doi: 10.1097/MD.0000000000032326.
   PubMed Web of Science ®Google Scholar
• Ma C, Xiang Q, Song G, et al. Quercetin and polycystic ovary syndrome. Front Pharmacol. 2022;13:1006678. doi: 10.3389/fphar.2022.1006678.
   PubMed Web of Science ®Google Scholar
• Liu S, Zhang Y, Yang F, et al. Modified Cangfu Daotan decoction ameliorates polycystic ovary syndrome with insulin resistance via NF-kappa B/LCN-2 signaling pathway in inflammatory microenvironment. Front Endocrinol (Lausanne). 2022;13:975724. doi: 10.3389/fendo.2022.975724.
   PubMed Web of Science ®Google Scholar
• Gao Z, Wang G, Ma X, et al. Troxerutin attenuates insulin resistance via pancreatic IL-22/JAK1/STAT3 signaling activation in dihydrotestosterone-induced polycystic ovary syndrome rats. Am J Physiol Endocrinol Metab. 2022;323(5):E405–E417. doi: 10.1152/ajpendo.00150.2022.
   PubMed Web of Science ®Google Scholar
• González F, Considine RV, Abdelhadi OA, et al. Inflammation triggered by saturated fat ingestion is linked to insulin resistance and hyperandrogenism in polycystic ovary syndrome. J Clin Endocrinol Metabolism. 2020;105(6):E2152–E2167. doi: 10.1210/clinem/dgaa108.
   PubMed Web of Science ®Google Scholar
• González F, Considine RV, Abdelhadi OA, et al. Saturated fat ingestion stimulates proatherogenic inflammation in polycystic ovary syndrome. Am J Physiol-Endocrinol Metabolism. 2021;321(5):E689–E701. doi: 10.1152/ajpendo.00213.2021.
   PubMed Web of Science ®Google Scholar
• Duica F, et al. Impact of increased oxidative stress on cardiovascular diseases in women with polycystic ovary syndrome. Front Endocrinol. 2021:12:614679.
   PubMed Web of Science ®Google Scholar
• Roy S, Abudu A, Salinas I, et al. Androgen-mediated perturbation of the hepatic circadian system through epigenetic modulation promotes NAFLD in PCOS mice. Endocrinology. 2022;163(10):bqac127. doi: 10.1210/endocr/bqac127.
   Web of Science ®Google Scholar
• Yao Q, Zou X, Liu S, et al. Oxidative stress as a contributor to insulin resistance in the skeletal muscles of mice with polycystic ovary syndrome. Int J Mol Sci. 2022;23(19):11384. doi: 10.3390/ijms231911384.
   PubMed Web of Science ®Google Scholar
• Nawrocka-Rutkowska J, Szydłowska I, Jakubowska K, et al. The role of oxidative stress in the risk of cardiovascular disease and identification of risk factors using AIP and castelli atherogenicity indicators in patients with PCOS. Biomedicines. 2022;10(7):1700. doi: 10.3390/biomedicines10071700.
   PubMed Web of Science ®Google Scholar
• Furat Rencber S, Kurnaz Ozbek S, Eraldemır C, et al. Effect of resveratrol and metformin on ovarian reserve and ultrastructure in PCOS: an experimental study. J Ovarian Res. 2018;11(1):55. doi: 10.1186/s13048-018-0427-7.
   PubMed Web of Science ®Google Scholar
• Moghetti P, Tosi F, Bonin C, et al. Divergences in insulin resistance between the different phenotypes of the polycystic ovary syndrome. J Clin Endocrinol Metab. 2013;98(4):E628–37. doi: 10.1210/jc.2012-3908.
   PubMed Web of Science ®Google Scholar
• Glueck CJ, Goldenberg N. Characteristics of obesity in polycystic ovary syndrome: etiology, treatment, and genetics. Metabolism. 2019;92:108–120. doi: 10.1016/j.metabol.2018.11.002.
   PubMed Web of Science ®Google Scholar